---
title: "Nurix Therapeutics 3Q 2026: Revenue $9.04M, EPS $(0.81) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292239293.md"
description: "Nurix Therapeutics reported Q3 2026 results with revenue of $9.04M, down 35.6% YoY, and a net loss of $89.54M, widening from the prior year's $43.46M loss. Diluted EPS was $(0.81) versus $(0.52). The decline stemmed from reduced collaboration revenue as initial terms concluded. Pipeline progress includes Phase 2 for bexobrutideg and Phase 1 trials for zelebrudomide and NX-1607. New collaborations with Roche and ongoing partnerships with Gilead, Sanofi, and Pfizer continue to support discovery."
datetime: "2026-07-09T20:21:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292239293.md)
  - [en](https://longbridge.com/en/news/292239293.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292239293.md)
---

# Nurix Therapeutics 3Q 2026: Revenue $9.04M, EPS $(0.81) — 10-Q Summary

Nurix Therapeutics reported third-quarter results for the period ended May 31, 2026, with revenue of $9.04M and a net loss of $89.54M, or diluted loss per share of $(0.81), versus revenue of $14.06M, net loss of $43.46M and diluted loss per share of $(0.52) in the year‑ago quarter.

**Financial Highlights**

-   Revenue was $9.04M for Q3 2026, compared with $14.06M in the year‑ago quarter; YoY change (35.6%).
-   Net income was a loss of $89.535M for Q3 2026, compared with a loss of $43.464M in the year‑ago quarter; loss widened by $46.071M YoY.
-   Diluted earnings per share was $(0.81) for Q3 2026, versus $(0.52) in the year‑ago quarter.

**Business Highlights**

-   Pipeline progress: continued Phase 2 for bexobrutideg and Phase 1 trials for zelebrudomide and NX‑1607, with enrollment and dose escalation advancing.
-   Collaborations and licensing: new Roche collaboration for bexobrutideg and ongoing partnerships with Gilead, Sanofi and Pfizer continue to support discovery and provide non‑dilutive funding.
-   Revenue mix shift: collaboration revenue declined as initial research terms concluded and license milestone timing reduced 2026 license revenue.
-   DEL‑AI platform: ongoing use of the proprietary DEL‑AI discovery platform supports multiple partnered programs and has generated $489M in non‑dilutive proceeds to date.
-   Operational scale‑up: increased spending on clinical trials, CMOs and contract research, along with higher personnel and stock‑based compensation to support growth.

Original SEC Filing: Nurix Therapeutics, Inc. \[ NRIX \] - 10-Q - Jul. 09, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [Moody Lynn Lieberson & Walker LLC Has $13.33 Million Stock Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/295782530.md)
- [Gilead Sciences declares Q3 2026 distribution of R$ 1.42 per unit for BRGILDBDR 000](https://longbridge.com/en/news/295004280.md)
- [Gilead's Yeztugo faces growth outlook questions](https://longbridge.com/en/news/294989257.md)
- [Pfizer repels Covid-19 sales tumble to raise 2026 guidance](https://longbridge.com/en/news/294878492.md)
- [Pfizer extends rally to seventh straight session](https://longbridge.com/en/news/295454569.md)